Analysis of the first part of the study as a parallel-group design placebo-controlled study
| Before citalopram | Citalopram 3 weeks | Citalopram 6 weeks | 3 weeks after citalopram | Before placebo | Placebo 3 weeks | Placebo 6 weeks | 3 weeks after placebo | |
|---|---|---|---|---|---|---|---|---|
| *Significant compared with run in: p<0.05. | ||||||||
| †Significant compared with placebo: p<0.05. | ||||||||
| Only those parameters where significance was reached are shown. | ||||||||
| No of days abdominal pain | 5.4 (0.3) | 4.8 (0.4) | 3.7 (0.5)*† | 4.0 (0.4)* | 5.4 (0.3) | 5.3 (0.3) | 5.2 (0.3) | 5.2 (0.4) |
| Severity of abdominal pain | 7.2 (0.6) | 6.2 (0.6) | 4.9 (0.7)*† | 5.4 (0.8)* | 7.8 (0.4) | 7.0 (0.4) | 7.0 (0.6) | 7.2 (0.8) |
| Worst episode of abdominal pain | 7.8 (0.6) | 6.6 (0.6)*† | 4.9 (0.8)*† | 5.4 (0.8) | 8.8 (0.3) | 8.7 (0.4) | 8.5 (0.4) | 7.7 (0.9) |
| No of days with bloating | 4.9 (0.5) | 4.2 (0.5)* | 3.4 (0.4)* | 4.2 (0.5) | 4.8 (0.5) | 4.5 (0.5) | 3.8 (0.6) | 4.2 (0.6) |
| Severity of bloating | 6.5 (0.8) | 5.1 (0.6) | 4.7 (0.7)* | 5.1 (0.7)* | 5.8 (0.7) | 5.4 (0.8) | 4.8 (0.7) | 5.2 (1.0) |
| Worst episode of bloating | 7.2 (0.9) | 6.6 (0.6) | 6.2 (0.5) | 6.1 (0.8) | 7.1 (0.8) | 6.2 (0.9)* | 7.0 (1.0) | 6.4 (0.9)* |
| No of days with incomplete evacuation | 3.8 (0.6) | 3.2 (0.4)* | 3.2 (0.5)* | 4.0 (0.5)† | 2.6 (0.5) | 2.7 (0.4) | 2.5 (05) | 2.3 (0.4) |
| Overall severity assessment | 7.1 (0.7) | 5.7 (0.7)*† | 5.0 (0.8)*† | 5.4 (0.9)* | 7.8 (0.2) | 7.7 (0.4) | 7.3 (0.5) | 6.8 (0.7) |
| No of days with impact on daily life | 5.2 (0.4) | 4.4 (0.3)* | 3.7 (0.5)* | 4.1 (0.5)* | 4.9 (0.2) | 5.0 (0.2) | 4.4 (0.2) | 4.5 (0.4) |
| Severity of impact on daily life | 6.5 (0.6) | 5.7 (0.7)* | 5.1 (0.8)* | 6.0 (0.7) | 6.9 (0.4) | 6.9 (0.4) | 6.4 (0.4) | 6.6 (0.7) |